MCID: CLP006
MIFTS: 45

Clopidogrel Resistance

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Clopidogrel Resistance

MalaCards integrated aliases for Clopidogrel Resistance:

Name: Clopidogrel Resistance 25
Cyp2c19-Related Poor Drug Metabolism 25
Poor Metabolism of Clopidogrel 25
Resistance to Clopidogrel 25

Classifications:



Summaries for Clopidogrel Resistance

Genetics Home Reference : 25 Clopidogrel resistance is a condition in which the drug clopidogrel is less effective than normal in people who are treated with it. Clopidogrel (also known as Plavix) is an antiplatelet drug, which means that it prevents blood cell fragments called platelets from sticking together (aggregating) and forming blood clots. This drug is typically given to prevent blood clot formation in individuals with a history of stroke; heart attack; a blood clot in the deep veins of the arms or legs (deep vein thrombosis); or plaque buildup (atherosclerosis) in the blood vessels leading from the heart, which are opened by placement of a small thin tube (stent).

MalaCards based summary : Clopidogrel Resistance, also known as cyp2c19-related poor drug metabolism, is related to drug metabolism, poor, cyp2c19-related and myocardial infarction. An important gene associated with Clopidogrel Resistance is CYP2C19 (Cytochrome P450 Family 2 Subfamily C Member 19), and among its related pathways/superpathways are Metabolism and Cytochrome P450 - arranged by substrate type. The drugs Clopidogrel and Ticlopidine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and bone, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Clopidogrel Resistance

Graphical network of the top 20 diseases related to Clopidogrel Resistance:



Diseases related to Clopidogrel Resistance

Symptoms & Phenotypes for Clopidogrel Resistance

MGI Mouse Phenotypes related to Clopidogrel Resistance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.86 ABCB1 CYP1A1 CYP1A2 ITGB3 KDR PTGS2
2 hematopoietic system MP:0005397 9.81 ABCB1 CYP1A1 ITGB3 KDR P2RY1 P2RY12
3 homeostasis/metabolism MP:0005376 9.7 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR
4 liver/biliary system MP:0005370 9.23 ABCB1 CYP1A1 CYP1A2 HMGCR ITGB3 KDR

Drugs & Therapeutics for Clopidogrel Resistance

Drugs for Clopidogrel Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113665-84-2, 120202-66-6 60606
2
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 55142-85-3 5472
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
4
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
5
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
6
Tirofiban Approved Phase 4 144494-65-5 60947
7
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
8
Cilostazol Approved, Investigational Phase 4,Not Applicable 73963-72-1 2754
9
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
10
Ranitidine Approved Phase 4 66357-35-5, 66357-59-3 3001055
11
Pantoprazole Approved Phase 4 102625-70-7 4679
12
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
13
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
14
Adenosine Approved, Investigational Phase 4 58-61-7 60961
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
16 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Atorvastatin Calcium Phase 4 134523-03-8
19 Calcium, Dietary Phase 4
20 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Cytochrome P-450 CYP2C19 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Anticholesteremic Agents Phase 4
23 Lipid Regulating Agents Phase 4
24 Rosuvastatin Calcium Phase 4 147098-20-2
25 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
26 Antimetabolites Phase 4
27 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hypolipidemic Agents Phase 4
29 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Purinergic P2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
32 Antirheumatic Agents Phase 4,Phase 3,Not Applicable
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Not Applicable
34 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
35 Analgesics Phase 4,Phase 3,Not Applicable
36 Cyclooxygenase Inhibitors Phase 4,Phase 3,Not Applicable
37 Antipyretics Phase 4,Phase 3,Not Applicable
38 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
39 Prasugrel hydrochloride Phase 4,Phase 3 389574-19-0
40 Interferon Inducers Phase 4
41 calcium heparin Phase 4
42 Adjuvants, Immunologic Phase 4
43 Antiviral Agents Phase 4
44 Antibiotics, Antitubercular Phase 4
45 Anti-Bacterial Agents Phase 4
46 Radiation-Protective Agents Phase 4
47 Anti-Infective Agents Phase 4
48 Protective Agents Phase 4,Not Applicable
49 Immunologic Factors Phase 4
50 interferons Phase 4

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
2 Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance Completed NCT00398463 Phase 4 Tirofiban;Placebo
3 Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation Completed NCT01094457 Phase 4 aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
4 Study of Policosanol to Improve Platelet Reactivity After Percutaneous Coronary Stent Implantation (PCI) Completed NCT01371058 Phase 4 high maintenance clopidogrel;routine dual antiplatelet;policosanol plus dual antiplatelet
5 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
6 Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention Completed NCT00404781 Phase 4 cilostazol in addition to aspirin and clopidogrel
7 Evaluation of the Influence of Statins and Proton Pump Inhibitors on Clopidogrel Antiplatelet Effects Completed NCT00930670 Phase 4 Rosuvastatin-omeprazole;Rosuvastatin-pantoprazole;Rosuvastatin-esomeprazole;Rosuvastatin-ranitidine;Atorvastatin-omeprazole;Atorvastatin-pantoprazole;Atorvastatin-esomeprazole;Atorvastatin-ranitidine
8 Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD Recruiting NCT03614832 Phase 4 Ticagrelor 90 mg;Clopidogrel 150 mg
9 Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm Recruiting NCT03581409 Phase 4 Aspirin;Prasugrel;Clopidogrel;Cilostazol
10 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
11 Efficacy and Safety Study of Ticagrelor Unknown status NCT01812330 Phase 3 Clopidogrel;Ticagrelor
12 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
13 The EFFect of hIgh Dose ClopIdogrel treatmENT in Patients With Clopidogrel Resistance Completed NCT01032668 Phase 3 Clopidogrel
14 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI). Completed NCT01109784 Phase 3 prasugrel;clopidogrel
15 Clopidogrel Reloading in Clopidogrel Resistant Patients With ACS Completed NCT00444132 Phase 3 clopidogrel
16 Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Completed NCT01155765 Phase 3 Prasugrel;Clopidogrel
17 Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment Completed NCT01304472 Phase 3 Prasugrel;Clopidogrel
18 Clopidogrel Resistance and Embolism in Carotid Artery Stenting Recruiting NCT02133989 Phase 3 Ticlopidine + Ginko biloba;Clopidogrel
19 Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Recruiting NCT03062462 Phase 2, Phase 3 Clopidogrel;ticagrelor
20 Antiplatelet Effects of Low-dose Ticagrelor and Standard-dose Clopidogrel in Chinese ACS Patients Recruiting NCT03381742 Phase 2, Phase 3 Ticagrelor;ticagrelor;ticagrelor;clopidogrel
21 Clopidogrel Pharmacogenomics Project Completed NCT01097343 Phase 2 clopidogrel 75 mg;Clopidogrel 150 mg
22 Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant Withdrawn NCT02008123 Phase 2 Primidone
23 Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel Completed NCT01396720 Phase 1 fluvoxamine;citalopharm
24 Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance Unknown status NCT01925872
25 Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk Unknown status NCT02624583
26 Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention Unknown status NCT01796873
27 Thromboelastography As A Tool for Possible Clopidogrel Resistance in The Patients Treated With Primary PCI for STEMI Unknown status NCT00517478
28 Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery Unknown status NCT02184884
29 Prasugrel Versus Clopidogrel in Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) Unknown status NCT01090336
30 Multiple Electrode Aggregometry & Clopidogrel Resistance Completed NCT01991093
31 Aspirin and Clopidogrel Resistance Study Completed NCT01039480
32 Resistance on Antithrombotic Drugs in Ischemic Heart Disease Completed NCT00742430
33 Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients Completed NCT01865890
34 clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad Completed NCT03667066 Clopidogrel
35 The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol Completed NCT00620646 Not Applicable aspirin, clopidogrel;aspirin, clopidogrel, cilostazol
36 Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention) Completed NCT02101411
37 Perioperative Aspirin Response in Patients Undergoing Vascular Surgery Completed NCT03587324 Not Applicable Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).
38 Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting Completed NCT02310191
39 Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent Completed NCT01816854
40 Clopidogrel Resistance in Stroke Patients From Different Ethnicities Not yet recruiting NCT03806894
41 ASA- and Clopidogrel-Responsiveness in Patients With Peripheral Arterial Occlusive Disease and Interventional Procedures Suspended NCT00593762
42 Clopidogrel Resistance and the Possibility of Its Affection Temporarily not available NCT00839345 clopidogrel

Search NIH Clinical Center for Clopidogrel Resistance

Genetic Tests for Clopidogrel Resistance

Anatomical Context for Clopidogrel Resistance

MalaCards organs/tissues related to Clopidogrel Resistance:

41
Heart, Testes, Bone, Kidney, Whole Blood, Colon, Bone Marrow

Publications for Clopidogrel Resistance

Articles related to Clopidogrel Resistance:

(show top 50) (show all 178)
# Title Authors Year
1
Association between CYP2C19 genotype and the additional effect of cilostazol to clopidogrel resistance in neuroendovascular therapy. ( 29915438 )
2018
2
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. ( 29347970 )
2018
3
Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients. ( 29350207 )
2018
4
Comment on "Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients". ( 29424732 )
2018
5
Low-Dose Prasugrel in Patients with Resistance to Clopidogrel for the Treatment of Cerebral Aneurysms. ( 30196683 )
2018
6
The Impact of Clopidogrel Resistance on Clinical Outcome of Iranian Patients Undergoing Percutaneous Coronary Intervention. ( 30127832 )
2018
7
Is Preoperative Clopidogrel Resistance a Predictor of Bleeding and Risks in Patients Undergoing Emergency CABG Surgery? ( 30184029 )
2018
8
Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance. ( 30422888 )
2018
9
Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. ( 28383427 )
2017
10
P2Y12 receptor gene polymorphism and the risk of resistance to clopidogrel: A meta-analysis and review of the literature. ( 28791856 )
2017
11
Prevalence of older in-patients at risk of clopidogrel resistance according to the STIB score. Results from REPOSI registry. ( 28410858 )
2017
12
The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population. ( 28358842 )
2017
13
Overcoming clopidogrel resistance: Three promising novel antiplatelet drugs developed in China. ( 28817486 )
2017
14
Review of aspirin and clopidogrel resistance in peripheral arterial disease. ( 28893489 )
2017
15
Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. ( 28329746 )
2017
16
A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance. ( 29167499 )
2017
17
Obesity, leptin, and thrombosis: Focus on clopidogrel resistance. ( 27774960 )
2016
18
Effects of genetic factors to stent thrombosis due to clopidogrel resistance after coronary stent placement. ( 26828987 )
2016
19
Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome. ( 28167470 )
2016
20
Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism. ( 27555873 )
2016
21
Potent and Orally Bioavailable Antiplatelet Agent, PLD-301, with the Potential of Overcoming Clopidogrel Resistance. ( 27594816 )
2016
22
Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population. ( 26935114 )
2016
23
Expression of miRNA-26a in platelets is associated with clopidogrel resistance following coronary stenting. ( 27347088 )
2016
24
Effect of obesity and serum leptin level on clopidogrel resistance. ( 27774962 )
2016
25
Allele Frequency Distribution of CYP2C19 Genotypes Associated with Clopidogrel Resistance in Russian Population. ( 27673643 )
2016
26
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. ( 26961113 )
2016
27
Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. ( 27133299 )
2016
28
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( 26340464 )
2016
29
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance. ( 26479956 )
2016
30
Tailored antiplatelet therapy in a patient with ITP and clopidogrel resistance. ( 25428265 )
2015
31
Risk factors for clopidogrel resistance in patients with ischemic cerebral infarction and the correlation with ABCB1 gene rs1045642 polymorphism. ( 25452814 )
2015
32
[CLINICAL AND PHARMACOLOGICAL FACTORS INFLUENCING RESISTANCE TO CLOPIDOGREL IN PATIENTS WITH CARDIOVASCULAR DISEASES]. ( 26117917 )
2015
33
Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients? ( 25893489 )
2015
34
Clopidogrel resistance after renal transplantation. ( 25792661 )
2015
35
Clopidogrel Resistance after Minor Ischemic Stroke or Transient Ischemic Attack is Associated with Radiological Cerebral Small-Vessel Disease. ( 26303791 )
2015
36
Clopidogrel resistance response in patients with coronary artery disease and metabolic syndrome: the role of hyperglycemia and obesity. ( 26347447 )
2015
37
Allele frequency distribution of CYP2C19*2 allelic variants associated with clopidogrel resistance in cardiac patients. ( 26170954 )
2015
38
The STIB score: a simple clinical test to predict clopidogrel resistance. ( 26567810 )
2015
39
Relation between the Change in Mean Platelet Volume and Clopidogrel Resistance in Patients Undergoing Percutaneous Coronary Intervention. ( 25322834 )
2015
40
Association of VEGFR-2 Gene Polymorphisms With Clopidogrel Resistance in Patients With Coronary Heart Disease. ( 25738571 )
2015
41
Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease. ( 26264906 )
2015
42
Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate. ( 26272977 )
2015
43
High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention. ( 24913197 )
2015
44
VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke. ( 25457586 )
2014
45
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. ( 24745016 )
2014
46
Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. ( 24996381 )
2014
47
Clopidogrel resistance: the way forward. ( 25443607 )
2014
48
Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population. ( 25112801 )
2014
49
Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. ( 23493759 )
2014
50
Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. ( 24449625 )
2014

Variations for Clopidogrel Resistance

Expression for Clopidogrel Resistance

Search GEO for disease gene expression data for Clopidogrel Resistance.

Pathways for Clopidogrel Resistance

Pathways related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 43)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2
2
Show member pathways
13.19 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3
Show member pathways
12.79 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
4
Show member pathways
12.21 CYP1A1 CYP1A2 CYP2C19 CYP2J2 CYP3A4
5
Show member pathways
12.18 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 PTGS2
6 12.02 ITGB3 P2RY1 P2RY12 VASP
7
Show member pathways
12 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 PTGS2
8 11.99 CYP2C19 CYP2C9 CYP2J2 PTGS2
9
Show member pathways
11.92 ITGB3 KDR PTGS2
10
Show member pathways
11.86 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
11 11.8 ITGB3 KDR PTGS2
12
Show member pathways
11.75 CYP1A1 CYP1A2 CYP3A4
13 11.7 ABCB1 CYP3A4 HMGCR
14
Show member pathways
11.7 CYP1A1 CYP1A2 CYP3A4 CYP3A5
15
Show member pathways
11.69 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
16
Show member pathways
11.66 ABCB1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
17
Show member pathways
11.58 ABCB1 CYP3A4 CYP3A5
18
Show member pathways
11.58 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
19 11.52 CYP1A1 CYP2J2 PTGS2
20 11.51 CYP1A1 CYP1A2 PTGS2
21
Show member pathways
11.44 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
22
Show member pathways
11.41 ABCB1 CYP3A4 CYP3A5
23 11.39 CYP1A1 CYP1A2 CYP2C19
24
Show member pathways
11.39 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
25 11.38 ABCB1 CYP1A2 CYP2C9 CYP3A4
26
Show member pathways
11.35 CYP1A1 CYP1A2 CYP3A4
27 11.34 ABCB1 CYP2C19 CYP2C9 CYP3A4 CYP3A5
28
Show member pathways
11.23 CYP1A2 CYP2C9 CYP3A4
29
Show member pathways
11.22 CYP2C9 CYP2J2 PTGS2
30 11.19 CYP1A1 CYP1A2 CYP2C9 CYP3A4
31 11.15 CYP1A2 CYP3A4 CYP3A5
32 11.08 ABCB1 CYP2C9 CYP3A4
33
Show member pathways
11.01 ABCB1 CYP1A1 CYP1A2 CYP2C9 CYP3A4 CYP3A5
34
Show member pathways
10.95 CYP1A1 CYP1A2 CYP3A4
35 10.95 ABCB1 CYP3A4 CYP3A5 PTGS2
36 10.94 ABCB1 CYP3A4 CYP3A5
37 10.93 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5 ITGB3
38 10.92 ABCB1 CYP3A4
39 10.87 ABCB1 CYP3A4 CYP3A5
40 10.8 CYP1A1 CYP1A2
41 10.73 ABCB1 CYP3A4 CYP3A5
42 10.51 CYP2C9 CYP2J2
43 10.36 CYP2C9 CYP3A4

GO Terms for Clopidogrel Resistance

Cellular components related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.96 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
2 endoplasmic reticulum membrane GO:0005789 9.81 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 intracellular membrane-bounded organelle GO:0043231 9.61 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
4 lamellipodium membrane GO:0031258 9.43 ITGB3 VASP
5 filopodium membrane GO:0031527 9.4 ITGB3 VASP
6 platelet alpha granule membrane GO:0031092 9.37 ITGB3 SELP
7 organelle membrane GO:0031090 9.23 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
8 membrane GO:0016020 10.22 ABCB1 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2

Biological processes related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 ABCB1 CYP1A1 CYP1A2 PTGS2
2 xenobiotic metabolic process GO:0006805 9.93 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4 CYP3A5
3 aging GO:0007568 9.89 CYP1A1 HMGCR P2RY1 PTGS2
4 response to lipopolysaccharide GO:0032496 9.88 CYP1A1 CYP1A2 PTGS2 SELP
5 response to organic cyclic compound GO:0014070 9.85 CYP1A1 CYP1A2 PTGS2
6 platelet activation GO:0030168 9.85 ITGB3 P2RY1 P2RY12
7 response to organic substance GO:0010033 9.83 CYP1A1 CYP1A2 PTGS2
8 cellular response to organic cyclic compound GO:0071407 9.8 CYP1A1 P2RY1 P2RY12
9 omega-hydroxylase P450 pathway GO:0097267 9.8 CYP1A1 CYP1A2 CYP2C19 CYP2C9
10 oxidative demethylation GO:0070989 9.78 CYP1A2 CYP2C9 CYP3A4 CYP3A5
11 heterocycle metabolic process GO:0046483 9.73 CYP1A1 CYP1A2 CYP2C19 CYP3A4
12 organic acid metabolic process GO:0006082 9.72 CYP2C19 CYP2C9 CYP2J2
13 drug metabolic process GO:0017144 9.72 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4
14 cellular response to ATP GO:0071318 9.71 P2RY1 P2RY12 PTGS2
15 drug catabolic process GO:0042737 9.71 CYP1A2 CYP2C9 CYP3A4 CYP3A5
16 lipid hydroxylation GO:0002933 9.7 CYP1A1 CYP3A4 CYP3A5
17 response to immobilization stress GO:0035902 9.68 CYP1A1 CYP1A2
18 calcium-mediated signaling using intracellular calcium source GO:0035584 9.68 KDR SELP
19 monoterpenoid metabolic process GO:0016098 9.67 CYP1A2 CYP2C19 CYP2C9 CYP3A4
20 G protein-coupled purinergic nucleotide receptor signaling pathway GO:0035589 9.66 P2RY1 P2RY12
21 vitamin D metabolic process GO:0042359 9.66 CYP1A1 CYP3A4
22 glial cell migration GO:0008347 9.65 P2RY1 P2RY12
23 negative regulation of blood vessel diameter GO:0097756 9.65 HMGCR PTGS2
24 exogenous drug catabolic process GO:0042738 9.65 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
25 adenosine receptor signaling pathway GO:0001973 9.64 P2RY1 P2RY12
26 toxin metabolic process GO:0009404 9.63 CYP1A1 CYP1A2
27 hydrogen peroxide biosynthetic process GO:0050665 9.62 CYP1A1 CYP1A2
28 negative regulation of norepinephrine secretion GO:0010700 9.62 P2RY1 P2RY12
29 positive regulation of ion transport GO:0043270 9.61 P2RY1 P2RY12
30 porphyrin-containing compound metabolic process GO:0006778 9.61 CYP1A1 CYP1A2
31 steroid catabolic process GO:0006706 9.6 CYP1A2 CYP3A4
32 dibenzo-p-dioxin metabolic process GO:0018894 9.58 CYP1A1 CYP1A2
33 alkaloid catabolic process GO:0009822 9.57 CYP3A4 CYP3A5
34 monocarboxylic acid metabolic process GO:0032787 9.56 CYP1A2 CYP2C9
35 long-chain fatty acid biosynthetic process GO:0042759 9.55 CYP1A1 CYP1A2 CYP2C9 CYP3A4 PTGS2
36 epoxygenase P450 pathway GO:0019373 9.35 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2
37 steroid metabolic process GO:0008202 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP3A4 CYP3A5
38 oxidation-reduction process GO:0055114 10.16 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
39 lipid metabolic process GO:0006629 10.04 CYP1A2 CYP2C9 CYP3A4 HMGCR PTGS2

Molecular functions related to Clopidogrel Resistance according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.99 CYP1A1 CYP1A2 CYP2C19 CYP3A4 ITGB3 PTGS2
2 iron ion binding GO:0005506 9.87 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.8 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
4 oxygen binding GO:0019825 9.78 CYP1A1 CYP2C19 CYP3A4 CYP3A5
5 steroid hydroxylase activity GO:0008395 9.77 CYP1A1 CYP2C19 CYP2C9 CYP2J2 CYP3A4
6 heme binding GO:0020037 9.76 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
7 aromatase activity GO:0070330 9.73 CYP1A1 CYP1A2 CYP2J2 CYP3A5
8 arachidonic acid epoxygenase activity GO:0008392 9.7 CYP2C19 CYP2C9 CYP2J2
9 estrogen 16-alpha-hydroxylase activity GO:0101020 9.67 CYP1A1 CYP3A4 CYP3A5
10 caffeine oxidase activity GO:0034875 9.63 CYP1A2 CYP2C9 CYP3A4
11 G protein-coupled purinergic nucleotide receptor activity GO:0045028 9.56 P2RY1 P2RY12
12 demethylase activity GO:0032451 9.55 CYP1A1 CYP1A2
13 vitamin D 24-hydroxylase activity GO:0070576 9.54 CYP1A1 CYP3A4
14 monooxygenase activity GO:0004497 9.5 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
15 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.17 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4
16 oxidoreductase activity GO:0016491 10.06 CYP1A1 CYP1A2 CYP2C19 CYP2C9 CYP2J2 CYP3A4

Sources for Clopidogrel Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....